Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-03.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89
1Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea
2University of Ottawa Eric Poulin Centre for Neuromuscular Disease, Ottawa, ON, Canada
3Interdisciplinary School of Health Sciences, Faculty of Health Sciences University of Ottawa, Ottawa, ON, Canada
4Korean Medical Research Center for Healthy Aging, Pusan National University, Yangsan, Korea
5Department of Korean Medical Science, Pusan National University School of Korean Medicine, Yangsan, Korea
6Service of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Geneva University Hospitals, Geneva, Switzerland
7Faculty of Medicine, University of Geneva, Geneva, Switzerland
8Department of Social Welfare, Division of Public Service, Dong-Eui University, Busan, Korea
9Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
10Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon, Korea
11Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
Copyright © 2020 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was reported.
Organization | Highlight | Reference |
---|---|---|
European Working Group on Sarcopenia in Older People (EWGSOP) | EWGSOP2 utilizes low muscle quality as the primary criterion of sarcopenia; muscle quality is directly the most solid proportion of muscle function. The diagnosis is made based on appendicular skeletal muscle mass calculated from dual-energy X-ray absorptiometry scan, skeletal muscle index, handgrip strength, and gait speed. | [10] |
Asian Working Group for Sarcopenia (AWGS) | Estimating both muscle quality (handgrip quality) and physical execution (common walk speed) as the screening test, specifying cutoff points of a similar index with EWGSOP2 based on Asian population characteristics. | [11] |
International Working Group on Sarcopenia (IWGS) | Emphasizes consideration of sarcopenia in bedridden and low gait speed patients, and uses a combination of gait speed and a measurement of low muscle mass to give the sarcopenia diagnosis. | [12] |
Foundation for the National Institutes of Health (FNIH) | Focuses on how physicians make differential diagnosis among older people with physical restrictions. Their recommendation contains cutoffs for both sexes, using similar indexes to EWGSOP2 and AWGS, but considers them in relationship with body mass index. | [13] |
MoA, mode-of-action; NCT, National Clinical Trial; GDF, growth differentiation factor; MAS, mitochondrial assembly; SARA-INT, Sarcopenia, A Double-blind Placebo Controlled Randomized INTerventional Clinical Trial; RyR, ryanodine receptor; FDA, U.S. Food and Drug Administration; RYR1-RM, ryanodine receptor type 1-related myopathies; 6MWD, 6-minute walk distance; PPARδ, peroxisome proliferator-activated receptor delta.